reference/22813176

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22813176

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	1995
issn	1527-7755 0732-183X
issueIdentifier	16
pageRange	1989-1995
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	1989
bibliographicCitation	Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012 Jun 01;30(16):1989–95. doi: 10.1200/jco.2011.39.0823. PMID: 22493419.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b87a4f0833331adf6277aa8f87c01e0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_975923b6c510b79aa2a75ee3e56a39bc http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7979-6261 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3211-6687 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b82b9adb5702699a94a3075da064f2c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2358a9179545c3a9fa4a55c090188bc2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd941387dbe33a2dc4bf31cff4686a39 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6dadf7b9db6504dadf325fc377dc4b63 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47df62e0a45004561379798c9fb45d75 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a38c155e5c247555734657006d265dbe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_04f9c0e6e72f9f68996e26f0ec74f485 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-5210-5344 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3cf06ef0e82f7ee8b79cf86d133ddd85 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_93da1a6a6238d1d98fe11589e8fe807f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df98dbce4326d76ba2b72fc497b4e41a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ba4b7df3af96f17e049cb6bd8b4d3eef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eb2c68cfadf2fe396a1a52fd496b45a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_daa3a19f6b6ffd309a450c74a176fc29 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8969-638X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_46e6fdd29972f0647137d6c6aa54de2f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b9443196044c4430ba4aa6642a2aad8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7ae2264178a53138e6b099dbd14520e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c5046c1d09028de48e1f4d179d4adb24 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1042-3771 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9e323914e90071f1cb5e21f77c9fdab3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_67f06c3b2c479ceb50b140426ce3af16
date	2012-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/22493419 https://doi.org/10.1200/jco.2011.39.0823
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023 https://portal.issn.org/resource/ISSN/1527-7755 https://portal.issn.org/resource/ISSN/0732-183X
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
discusses	http://id.nlm.nih.gov/mesh/M0008631 http://id.nlm.nih.gov/mesh/M0018336 http://id.nlm.nih.gov/mesh/M0026156 http://id.nlm.nih.gov/mesh/M0005485 http://id.nlm.nih.gov/mesh/M0028048 http://id.nlm.nih.gov/mesh/M0473129 http://id.nlm.nih.gov/mesh/M0023488
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D020360 http://id.nlm.nih.gov/mesh/D015251Q000008 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D001943Q000601 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D000077341 http://id.nlm.nih.gov/mesh/D011799Q000008 http://id.nlm.nih.gov/mesh/D018719Q000378 http://id.nlm.nih.gov/mesh/D005472Q000008 http://id.nlm.nih.gov/mesh/D017239Q000008 http://id.nlm.nih.gov/mesh/D018719Q000037 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D003520Q000008 http://id.nlm.nih.gov/mesh/D000971Q000009
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9548828 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41867 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID208908 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3385 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7922

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136090536 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127494626

Total number of triples: 85.